FOUNDATIONONE® LIQUID

Clinical Data Summary

Blood-First Assay Screening Trial (BFAST)

*BFAST is the first prospective study to use only blood-based next generation sequencing (NGS) to detect specific fusions with the aim of selecting treatment for people with advanced non-small cell lung cancer (NSCLC), without the need for tissue biopsy.**

Results from Cohort A

Patients tested for *ALK* fusions and, if positive, treated with Alecensa® (alectinib)

2,219 patients received liquid biopsy testing at Foundation Medicine

↓

119 patients tested positive for *ALK* fusions

↓

87 patients enrolled and treated with Alecensa® (alectinib)†



Study met its primary endpoint!



Frequency of *ALK* fusions in BFAST

FoundationOne Liquid is the only liquid biopsy test that has demonstrated the ability to identify patients with *ALK* fusions in a global prospective trial for metastatic NSCLC **at similar frequencies historically published with tissue testing.**

5.4%
frequency of *ALK* fusions in BFAST with **FoundationOne Liquid**

vs.

5%‡
frequency of *ALK* fusions using tissue testing **historically published**

36 institutions, 15 countries

FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global registrational trial for patients with newly diagnosed, metastatic NSCLC.

FoundationOne Liquid is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine.

Foundation Medicine is the only company with a proven portfolio of comprehensive genomic profiling tests—from a blood draw or tissue biopsy—that has demonstrated clinical utility in metastatic, newly diagnosed NSCLC.¶

Fast results in less than two weeks‖

Tests include guideline-recommended genes in NSCLC

EGFR | *ALK* | *ROS1* | *BRAF* | *RET* | *MET* | *ERBB2*

Simplified and expertly curated reports to help inform clinical decision making

References

* LBA81_PR 'Phase II/III blood first assay screening trial (BFAST) in patients (pts) with treatment-naïve NSCLC: initial results from *ALK*+ cohort' will be presented by Shirish Gadgeel during the proffered paper session on Monday, 30 September 2019, 08:30-10:00 CEST in Madrid Auditorium (Hall 2). Annals of Oncology, Volume 30, Supplement 5, October 2019.

† There were 32 patients identified as *ALK*-Positive and not enrolled on the trial due to other ineligibility criteria, patient or investigator decision, or other reasons.

‡ Dearden et al. Ann Oncol. 2013 Sep; 24(9): 2371–2376.

‖ Typical turnaround time from receipt of specimen

¶ FoundationOne®Heme is excluded from this claim. FoundationOne Heme is a laboratory developed test that was developed and its performance characteristics determined by Foundation Medicine.

FOUNDATION MEDICINE